{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.4","value":"-0.3"},{"groupId":"OG001","spread":"22.6","value":"2.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"},{"groupId":"OG001","value":"47"}],"units":"Participants"}],"description":"Subjects were asked to rate their general state of health on a Visual analog scale (in millimeter \\[mm\\]) ranging from 0 (worst state of health) to 100 (best conceivable state of health) mm.","dispersionType":"Standard Deviation","groups":[{"description":"bortezomib (Velcade) 1.6 mg/m² bolus injection on Days 1, 8, 15 and 22 every 5 weeks for 4 cycles","id":"OG000","title":"Bortezomib"},{"description":"no treatment, observation only","id":"OG001","title":"Non-treated Control"}],"paramType":"MEAN","populationDescription":"FAS included all the randomized subjects who were eligible for efficacy analysis, that is, excluding subjects who did not have baseline and/or post-baseline data. Missing data was imputed by last observation carried forward (LOCF) method.","reportingStatus":"POSTED","timeFrame":"Baseline up to end of study (approximately 4 years 7 months)","title":"Change From Baseline in Quality of Life Assessed by Euro Quality of Life (EQ-5D)","type":"SECONDARY","unitOfMeasure":"millimeter (mm)"}